Sign In
Buy LIXT
$7.30
-0.180 (-2.41%)
At Close: Jun 23, 2026
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
11:17am, Tuesday, 03'rd Aug 2021
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of sta
A Pre-Clinical Study Reports that LB -100 Potentiates Standard Therapy f or Small Cell Lung Cancer Providing a Strong Rational e f or a Clinical Trial o f LB -100 i n Small Cell Lung Cancer Recently I
Altadena, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage drug discovery company developing pharmacologically active drugs for improving cancer
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the W
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
09:35am, Wednesday, 07'th Jul 2021
Presentation to highlight Company's current clinical stud y of lead compound LB-100 for Small Cell Lung Cancer
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
09:35am, Wednesday, 02'nd Jun 2021
EAST SETAUKET, NY, June 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in can
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
09:35am, Wednesday, 12'th May 2021
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq : LIXT) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as
Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
09:35am, Tuesday, 13'th Apr 2021
EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing p
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
09:35am, Wednesday, 03'rd Mar 2021
EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in c
LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnolog
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.
03:41pm, Tuesday, 02'nd Mar 2021
JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offeri
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
10:30am, Tuesday, 02'nd Mar 2021
East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer
Why Morphic, Athenex, Lixte Biotech Are Moving Today
01:02pm, Monday, 01'st Mar 2021
Morphic Holding Inc (NASDAQ: MORF), Athenex Inc (NASDAQ: ATNX) and Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) are among the healthcare movers on Monday. Morphic Jumps On Data: Morphic, a biopharm
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
08:45am, Monday, 01'st Mar 2021
East Setauket, March 01, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in canc
